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RAPID COMMUNICATION
Myofibroblast and a1(III) collagen expression in experimental
tubulointerstitial nephritis
WINs0N W. TANG, GWYNETH Y. VAN, and MEIYING Qi
Department of Pathology, Amgen Inc., Thousand Oaks, California, USA
Myofibroblast and a1 (LII) collagen expression in experimental tubulo-
interstitial nephritis. Despite the importance of tubulointerstitial fibrosis
as a predictor of renal function in patients with primary glomerular
disease, the identity of the cell(s) that is the source of interstitial collagen
production remains unknown. The present study was performed to
identify the site of aj(JII) production during the development of tubulo-
interstitial fibrosis. We studied a model of experimental tubulointerstitial
nephritis associated with puromycin aminonucleoside (PAN) nephrosis.
There was a twofold increase in renal cortical a 1(111) mRNA expression
coincident with the onset of tubulointerstitial myofibroblasts infiltration in
rats with PAN nephrosis beginning on day 6, which increased to a fivefold
difference by day 10. There were 60.8 40.3 myofibroblast/mm2 within the
renal tubulointerstitium of rats with PAN nephrosis on day 6 that peaked
at 240.2 11.1 myofibroblast/mm2 on day 14, which then declined to
43.7 9.8 myofibroblast/mm2 by day 21. By combining in situ hybridiza-
tion with immunohistochemistry, a1(III) mRNA expression was colocal-
ized to cells that labeled for a-smooth muscle actin identifying them as
myofibroblasts. Interestingly, the major site of a1(III) mRNA expression
shifted to tubuloepithelial cells with the waning of myofibroblast infiltra-
tion on day 21. To determine if PDGF-BB induced myofibroblasts to
synthesize a(III) mRNA, we examined kidneys from rats that had been
treated with PDGF-BB (5 mg/kg/day). a1(IlI) mRNA expression also
localized to cells that labeled for a-smooth muscle actin. These data
demonstrate the cellular source of a1(III) production within the renal
tubulointerstitium following injury, and suggest that PDGF-BB may be
mediating this production.
The development of tubulointerstitial nephritis (TIN) corre-
lates closely with the loss of renal function in patients with chronic
glomerular disease [1—4]. Despite its importance, the pathogene-
sis of TIN is not particularly well understood at the present time.
Currently, it is believed that inflammation occurring either locally
or within the glomerulus may precipitate injury through the
production of cytokines, lysosomal enzymes and reactive oxygen
species [5]. This is followed by the excessive synthesis, secretion,
and deposition of cxtracellular matrix components (ECM) by cells
within the tubulointerstitium in response to autocrine anti/or
paracrine growth factors [6].
The latter was confirmed recently with the demonstration that
platelet-derived growth factor B (PDGF-B) induced tubulointer-
stitial collagen III accumulation [7], However, despite these
advances the identity of the cell(s) that is the site of interstitial
Received for publication September 12, 1996
and in revised form November 1, 1996
Accepted for publication November 7, 1996
© 1997 by the International Society of Nephrology
collagen synthesis remains unknown. To date, attention has
focused primarily upon tubulointerstitial fibroblasts and tubulo-
epithelial cells [8, 9]. Both of these cells have been shown to
synthesize procollagens types I and III in addition to other ECM
molecules in vitro [8, 9]. Nonetheless, a role for these cells in the
pathogenesis of tubulointerstitial fibrosis in vivo remains to be
determined. Recently a third cell type, the myofibroblast, has been
identified within the tubulointerstitium of fibrotic kidneys and
represents another potential cell type upon which growth factors
may exert an effect [10]. Indeed, a striking association between the
appearance of tubulointerstitial myofibroblasts, and an increase in
collagen III mRNA and protein expression has been reported [7].
Myofibroblasts are terminally differentiated cells with morpho-
logic features intermediate between those of fibroblasts and
smooth muscle cells [ii, 12]. Thus, the cell retains the biologic
properties of fibroblast synthesizing interstitial collagens I and III,
and at the same time expresses a-smooth muscle actin, a charac-
teristic of the vascular smooth muscle cell [13]. Recently, the
expression of a-smooth muscle actin by activated fibroblast was
shown to retard its motility in vitro, enabling the cell to form focal
adhesions [14]. The present experiments were performed to test
the hypothesis that myofibroblasts are the source of interstitial
collagen production during the development of tubulointerstitial
fibrosis in a model of experimental TIN associated with puromy-
cm aminonucleoside (PAN) nephrosis.
Methods
Experimental models
Puromycin aminonucleoside nephrosis. Twenty-seven Lewis rats
were injected with either puromycin aminonucleoside (15 mg/kg
body wt, N = 18) or saline vehicle (N = 9) intravenously through
a tail vein. Rats with PAN nephrosis were sacrificed on days 4, 6,
8, 10, 14, and 21 (N = 3), while control rats were sacrificed on days
6, 10 and 21 (N 3). A 24 hour urine was obtained on the day of
sacrifice and urinary protein excretion was quantitated by the
sulfosalycylic acid method with rat albumin (Sigma Chemical Co.,
St. Louis, MO, USA) serving as the standard [15].
PDGF-BB administration. Renal tissue from a previous study in
which Lewis rats had been administered recombinant human
PDGF-BB was also examined to determine the effect of this
growth factor on myofibroblast collagen III expression [7]. Rats
were injected with 5 mg/kg of PDGF-BB or saline vehicle daily fo:r
a total of seven days. The animals were sacrificed on days 1, 3, 5,
and 7.
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Morphologic studies
Rat kidneys were fixed in 10% formalin for light microscopy
and immunohistochemistry. Histologic sections were stained with
the periodic acid-Schiff reaction and hematoxylin counterstain.
Deparaffinized sections were labeled with monoclonal antibodies
(Abs) to rat macrophage/moriocyte (ED-i, Harlan Bioproducts
for Science, Indianapolis, IN, USA) or a-smooth muscle actin
(Dako Inc., Carpinteria, CA, USA). The monoclonal Abs were
detected with horseradish peroxidase ABC reagents (BioTek,
Santa Barbara, CA, USA) and 3,3'-diaminobenzidine tetrahydro-
chloride (DAB) as the chromagen. To determine the extent of
myofibroblast infiltration, the number of a-smooth muscle actin
labeled cells in 30 consecutive tubulointerstitial fields of a uniform
area (0.17 mm2) was counted. The data were normalized to the
number of myofibroblast/mm2 and presented as the mean SD.
Quantitation of al (III) mRNA
The details of the RNase protection assay and the preparation
of the rat al(1l1) (304 nucleotides) and GAPDH (104 nucleo-
tides) riboprobes were reported previously [7, 161. Briefly, total
RNA from the renal cortex of control or PAN nephrotic rats was
prepared by acid phenol/chloroform extraction and frozen at
—70°C. Anti-sense riboprobes were prepared by in vitro transcrip-
tion with either T7 or SP6 RNA polymerases (Ambion, Austin,
TX, USA), and the incorporation of a 32P-UTP (Amersham
Corp, Arlington Hts, IL, USA) at 37°C. The riboprobes were
purified by electrophoresis on 6% polyacrylamide gel and then
eluted with 0.5 M NH4OAc. Five micrograms of RNA was
hybridized with 1 >< i0 counts of each 32P-UTP-labeled ribo-
probe for 14 to 16 hours at 56°C. The unhybridized RNA was
digested with RNase A and Ti (Ambion) at 30°C for one hour.
The RNases were then digested with proteinase K (Boehringer
Mannheim) at 37°C for 30 minutes. After phenol/chloroform
extraction and sodium acetate/ethanol precipitation, the samples
were electrophoresed on 6% polyacrylamide gel. The radioactivity
of the protected 32P-UTP labeled riboprobes was quantitated by a
Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA).
The blots were computer-generated on the monitor, and rectan-
gles were circumscribed around the bands of interest. The radio-
activity within each rectangle was calculated by the computer and
then normalized for each pixel. To ensure that there was a
constant quantity of RNA within each sample, the final values
were factored relative to the GAPDH mRNA levels. Data are
presented as the mean SD.
Immunohistochemistiy/in situ hybridization
Sense and anti-sense al (III) riboprobes were prepared by in
vitro transcription with the incorporation of 33P-UTP (New En-
gland Nuclear, Boston, MA, USA), as described above. Immuno-
histochemistry with the anti-a-smooth muscle actin monoclonal
Ab was performed on deparaffinized sections (3 to 5 jim), as
described above. The slides were then digested with proteinase K,
and hybridized overnight with the 33P-UTP labeled sense and
antisense a1(III) riboprobes at 50°C. After successive washes with
increasing stringency, the slides were dipped in Kodak NTB2
emulsion and exposed at 4°C for three weeks. The slides were
developed at 15°C in Kodak D19, fixed, and then counterstained
with hem atoxylin and eosin. The percentage of cells that colabeled
for a-smooth muscle actin and al(III) mRNA was estimated by
counting 500 cells that expressed al(III) mRNA.
Results
Morphology
There were no pathologic abnormalities within the kidneys of
rats four days after the administration of PAN. However, begin-
ning on day 6, protein reabsorption droplets and proteinacious
casts were prominent within cortical and medullary tubules. In
addition, there was an interstitial expansion with disruption of the
normal tubular and capillary aposition by macrophages/mono-
cytes and other mononuclear cells. Approximately 14% of the
mononuclear cells infiltrating the tubulointerstitium on day 6 were
monocytes/macrophages. By day 8, tubular atrophy, tubular drop-
out, and giant dilated tubules resembling pseudocysts were de-
tected. The macrophage/monocyte infiltrate peaked on day 10 and
declined thereafter. By day 21, the majority of the tubules had
re-epithelialized, although occasional tubules had thickened base-
ment membranes. These morphologic changes were associated
with the development of proteinuria on day 4 (27 7 mg/day) that
peaked on day 14 (156 20 mg/day) and declined by day 21
(129 42 mg/day).
a-smooth muscle actin expression
The majority of the mononuclear cells infiltrating the tubuloint-
erstitium (> 80%) did not label with the monoclonal Ab ED-i.
Based upon previous work from our laboratories and others [7,
17—22], we suspected that these cells were myofibroblast, and thus
performed immunohistochemistry with an Ab to a-smooth muscle
actin. Myofibroblasts were first detected within the tubulointersti-
tium of rats with PAN nephrosis on day 6 (60.8 40.3 cells/mm2),
and increased to 154.1 15.3 cells/mm2 by day 8. The number of
infiltrating myofibroblasts rapidly peaked at 232.8 9.1, and
240.2 11.7 cells/mm2 on days 10 and 14, respectively. Thereaf-
ter, the myofibroblast infiltration declined markedly to only
43.7 9.8 cells/mm2 by day 21. In contrast, only vascular smooth
muscle cells labeled for a-smooth muscle actin in the kidneys of
control rats (days 6, 10, 21) and in rats with PAN nephrosis on day
4.
Quantitation of steady state mRNAs
al(III,). The steady-state expression of al(III) mRNA within
the renal cortex of rats with PAN nephrosis on day 4 was similar
to that of the control rats. However, beginning on day 6 there was
a 2.5-fold increase in al(TII) mRNA relative to GAPDH mRNA,
which increased to a 4.5-fold difference from control rats on days
10. It slowly declined thereafter, although it was still three-fold
greater than that of control rats on day 21 (Fig. 1). The increase
in collagen III mRNA has been previously reported to be
associated with increased tubulointerstitial collagen III accumu-
lation in PAN nephrosis [23].
Immunohistochemistty/in situ hybridization
The site(s) of al(lII) mRNA synthesis within the tubulointer-
stitium of rats with PAN nephrosis were examined by combining
immunohistochemistry with in situ hybridization. There was a low
basal expression of al(l1I) mRNA, which was limited to tubular
cells in control rats and in rats with PAN nephrosis on day 4.
However, with the onset of myofibroblast infiltration on day 6
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Fig. 1. A. Autoradiograph of a RNase protection
assay demonstating increased a (III) steady state
mRNA expression relative to GAPDH mRNA.
PAN nephrosis rats (+) were sacrificed on days
4, 6, 8, 10, 14 and 21, while control rats (—)
were sacrificed on days 6, 10 and 21. B. The
autoradiographs were quantitated on a
phosphorous imager and the results were
25 summarized. Each data point represents themean SD of three rats that were assayed
individually. Symbols are: (LII) PAN nephrosis
rats; (•) control rats.
Fig. 2. Representative photomicrographs of kidneys from rats with PAN nephrosis which had been immunolabeled with an Ab to a-smooth muscle actin
followed by in situ hybridization with a 33P anti-sense a1(III) riboprobe. There was colocalization of the labeling for a-smooth muscle actin and a1(III)
mRNA identifying myofibroblasts as the site of a(III) synthesis on days 6 (A) and 14 (B). However, by day 21, the number of myofibroblasts had
markedly declined and tubular epithelial cells are now the primary site for a1(III) mRNA production (C). By comparison, the a1(1II) sense riboprobe
did not hybridize with nephrotic kidneys on day 21(D).
Fig. 3. Representative photomicrographs of kidneys from rats infused with PDGF-BB (5 mg/kg body wt) that had been immunolabeled with an Ab to
a-smooth muscle actin followed by in situ hybridization with a 33P anti-sense a,(III) riboprobe. One day following PDGF-BB administration (A), only
occasional tubular cells expressed a(III) mRNA. Similarly, a1(HI) mRNA expression was minimal in the kidney of rats which had received the saline
vehicle for seven days (D). However, with myofibroblast infiltration on days 3 (B) and 7(C), hybridization with the anti-sense a1(III) riboprobe increased
and were localized to cells labeled for a-smooth muscle actin.
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(Fig. 2A), strong expression of al(III) mRNA could be localized
to cells within the tubulointerstitial compartment. Approximately
90% of the cells that expressed al(1II) mRNA colabeled for
a-smooth muscle actin, identi!'ing them as myofibroblasts. At the
peak of myofibroblast infiltration in rats with PAN nephrosis on
day 14 (Fig. 2B), > 95% of the cells that labeled for al(III)
mRNA were myofibroblasts. However, the cellular source of
al(III) mRNA changed markedly in nephrotic rats by day 21.
With the waning of myofibroblast infiltration, tubular epithelial
cells were now the major site of al(III) mRNA production (Fig.
2C), with only 30 to 35% of the cells colabeling for al(III) mRNA
and a-smooth muscle actin. The hybridization with the al (III)
anti-sense riboprobe was specific, since parallel experiments per-
formed with a sense riboprobe in rats with PAN nephrosis on day
21 did not produce a signal (Fig. 2D).
In a previous study [7], we had demonstrated that PDGF-BB
induces tubulointerstitial myofibroblast infiltration, and collagen
III mRNA and protein accumulation. In order to determine the
site of collagen III synthesis in these animals, we performed
immunohistochemistry and in situ hybridization on paraffin em-
bedded kidneys from this previous study. Myofibroblasts were
again found to colabel with the al(III) anti-sense riboprobe three
and seven days following PDGF-BB administration (Figs. 3 B, C).
In contrast, only occasional tubular cells labeled for al(III)
mRNA one day after PDGF-BB administration (Fig. 3A), at a
time when myofibroblasts were absent. Similarly, al(III) mRNA
expression was minimal in the kidneys of control rats that had
been administered saline vehicle for a period of seven days (Fig.
3D).
Discussion
The results of this study demonstrate an important role for the
myofibroblast in the pathogenesis of tubulointerstitial fibrosis
associated with glomerular disease. In a previous study, we
presented data to suggest an association between myofibroblast
infiltration and tubulointerstitial collagen III accumulation [71.
Other investigators have also noted an association between myo-
fibroblast infiltration and tubulointerstitial fibrosis [18—22]. Myo-
fibroblasts were first detected focally within the tubulointerstitium
six days after induction of PAN nephrosis. This was consistent
with previous studies that have shown myofibroblasts to be a
prominent component of the tubulointerstitial compartment in
glomerular disease [19—22]. By combining immunohistochemistry
with in situ hybridization, myofibroblasts were shown to be the
predominant cell type (90% on day 6) responsible for the in-
creased expression of al(III) mRNA in the early phase of injury
in this model of TIN associated with PAN nephrosis. This
conclusion is also supported by the similarity in the kinetics of the
al(lII) steady state mRNA expression and the appearance of
tubulointerstitial myofibroblast, Thus, an increase in al(III)
mRNA did not occur with the development of proteinuria on day
4, but coincided with the onset of myofibroblast infiltration on day
6.
The number of infiltrating myofibroblasts declined markedly by
day 21, while the steady state mRNA expression of a1(III) within
the renal cortex remained essentially unchanged. This suggested
that a different cell type was now the source of a 1(111) mRNA
synthesis. Indeed, Figure 2C demonstrates that al(III) mRNA
synthesis had localized within tubular epithelial cells on day 21.
This observation would explain the thickening of the tubular
basement membrane noted in rats with PAN nephrosis on day 21.
Thus, there is a bimodal pattern of al(III) mRNA expression in
which myofibroblasts are the predominant site of synthesis early,
while tubular epithelial cell are the source of al(III) production
during the later phase. The relative contribution of these two cell
types to the pathologic, as opposed to the reparative, production
of al(III) remains uncertain. In the model of TIN presently
studied, myofibroblast infiltration was relatively short-lived (—2
weeks), and repair with restoration of the tubulointerstitial archi-
tecture occured. In contrast, tubulointerstitial myofibroblasts in-
filtration persist in chronic glomerular disease associated with
tubulointerstitial fibrosis in humans, suggesting that the produc-
tion of al (III) by this cell type is pathologic [19, 20]. However, this
assumption remains speculative and will require confirmation in
animal models of chronic tubulointerstitial fibrosis.
The appearance of myofibroblasts coincided with increased
steady-state expression of a1 (III) mRNA within the tubulointer-
stitium beginning on day 6 in rats with PAN nephrosis. We have
previously shown that the appearance of myofibroblasts within the
tubulointerstitium is in part mediated by the growth factor
PDGF-BB. In addition, growth factors are believed to induce the
synthesis ECM, in which excessive accumulation may lead to
tubulointerstitial fibrosis [6]. An increase in TGF-f3 expression has
been previously reported by Eddy and colleagues in tubulointer-
stitial fibrosis associated with PAN nephrosis [23, 24]. In prelim-
inary studies, we have found an increase in PDGF-B mRNA
expression in the renal cortex of rats with PAN nephrosis, relative
to control rats, beginning on day 6. This suggested a potential role
for growth factors in the pathogenesis of tubulointerstitial fibrosis.
To determine if PDGF-B induces myofibroblasts to express
a1(III) mRNA, we examined renal tissue from an earlier study in
which rats had been administered PDGF-BB intravenously (5
mg/kg/day) [7]. The co-localization of a(III) mRNA and a-smooth
muscle actin within tubulonterstitial cells confirmed that PDGF-BB
can induce the myofibroblasts to synthesize csl(III) mRNA. We have
previously demonstrated that the increase in al (III) mRNA is
associated with increased expression of this protein within the
tubulointerstitium of these rats [7].
An important question that remains unanswered relates to the
origin of tubulointerstitial myofibroblasts. In contrast, glomerular
myofibroblasts have been shown both in vitro and in vivo to arise
from mesangial cells [25, 26]. By comparison, myofibroblasts are
believed to arise from the differentiation of fibroblasts during
cutaneous wound repair/fibrosis [27]. Although tempting, it would
be inappropriate to draw a similar conclusion in renal fibrosis,
since tubulointerstitial fibroblasts have been shown to differ from
cutaneous fibroblasts in vitro [28]. To date, we have been unable
to induce a-smooth muscle actin expression with PDGF-BB in
cultured murine tubulointerstitial fibroblasts (W.W. Tang and J.S.
Yee, unpublished observation). Nonetheless, differentiation of
fibroblasts into myofibroblasts may explain an interesting obser-
vation noted by Jones and coworkers. These investigators had
previously demonstrated an approximate 50% decline in the
number of tubulointerstitial fibroblasts one week after the admin-
istration of PA, which nadired at approximately 5% of normal at
two weeks and did not recover until five weeks [23]. It is tempting
to speculate that this decline resulted from the differentiation of
fibroblasts into myofibroblasts.
The vascular smooth muscle cells surrounding blood vessels
that constituitively express a-smooth muscle actin are an unlikely
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source, since they consistently did not label for a1 (III) mRNA in
the present study. Other potential candidates includes the type II
interstitial cell (macrophage) and the dendritic cell as described in
other studies [29, 30]. Recently, Strutz et al identified a cDNA
encoding a fibroblast specific protein (FSP), which they termed
FSP1. It would be interesting to label myofibroblasts for FSP1 to
determine if myofibroblasts also express this protein. Further-
more, Strutz et al noted increased expression of FSP1 by the
tubular epithelium in a murine model of tubulointerstitial fibrosis
eight weeks following the induction of injusy, and postulated that
parenchymal epithelia may transdifferentiate into fibroblasts [31].
Thus, the tubular epithelial cell is another potential candidate for
the cellular origin of the myofibroblasts. Unfortunately, determin-
ing the origin of the myofibroblast will be difficult, since at present
methods for tracking the fate of cells in vivo are unavailable.
In conclusion, these experiments demonstrate a bimodal pat-
tern of al(III) mRNA expression and an important role for the
myofibroblast in the pathogenesis of tubulointerstitial fibrosis.
Immediately following injury, myofibroblasts infiltrate the tubu-
lointerstitium and are the source of al(III) mRNA synthesis,
while tubular cells are more important in the later phase. To our
knowledge, this is the first demonstration of the cellular sources of
al(III) mRNA production during renal fibrogenesis. In addition,
myofibroblasts are likely to contribute to the fibrotic process
through its role in collagen contraction mediated by the a-smooth
muscle actin filaments [32]. Although the origin of the myofibro-
blast remains unknown, these data suggest that this cell may
represent a potential target for therapeutic intervention in tubu-
lointerstitial fibrosis.
Reprint requests to Winson W. Tang, M.D., Amgen Inc., 1840 DeHavilland
Drive, MS 24-2-A, Thousand Oaks, California 91320, USA.
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